Search En menu ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages
    Reference: 20180623
    Release date: 12 April 2019

    Promoter – Financial Intermediary

    ADVICENNE SA

    Location

    Description

    The project supports the Promoter's research and development (R&D) investments to progress a pipeline of new therapeutics across the pharmaceutical value-chain.

    Objectives

    R&D investments concern pediatric-friendly therapeutics adressing critical unmet medical needs in the field of rare and orphan diseases across the pharmaceutical value-chain.

    Sector(s)

    • Services - Professional, scientific and technical activities

    Proposed EIB finance (Approximate amount)

    EUR 20 million

    Total cost (Approximate amount)

    EUR 51 million

    Environmental aspects

    R&D investments are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.

    Procurement

    The project promoter is a private company not operating in the utilities sector and not having the status of a contracting authority. Thus it is not covered by EU Directives on procurement. However, the Promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.

    Status

    Signed - 2/07/2019

    Disclaimer

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Related tags

    France Services